An Increasing Role for Trabectedin in Gynecological Cancers
- 1 May 2011
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 21, S3-S5
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.Journal of Clinical Oncology, 2010
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM)Journal of Clinical Oncology, 2009
- Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine SarcomasInternational Journal of Gynecological Cancer, 2009
- International Federation of Gynecology and Obstetrics (FIGO) staging system revised: what should be considered critically for gynecologic cancer?Journal of Gynecologic Oncology, 2009
- Systemic therapy for advanced uterine sarcoma: A systematic review of the literatureGynecologic Oncology, 2005
- Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEuropean Journal of Cancer, 2002